Kronos Bio(KRON) - 2024 Q4 - Annual Results

Financial Performance - Net loss for Q4 2024 was $25.8 million, or$0.43 per share, with a total net loss of $86.1 million, or$1.43 per share for the full year, an improvement from $112.7 million in 2023[2][4] - Total operating expenses for Q4 2024 were$29.4 million, with a total of $102.7 million for the full year, down from$128.4 million in 2023[4] - Research and development expenses for Q4 2024 were $8.4 million, with a total of$48.7 million for the full year, a decrease from $84.5 million in 2023[2][4] - General and administrative expenses for Q4 2024 were$4.9 million, totaling $24.6 million for the full year, down from$39 million in 2023[2][4] - Impairment of long-lived assets and restructuring charges for Q4 2024 were $16.1 million, with a total of$29.5 million for the full year, compared to $4.9 million in 2023[2][4] Assets and Liabilities - Cash, cash equivalents, and investments as of December 31, 2024, were$112.4 million, down from $175 million in 2023[6] - Total assets as of December 31, 2024, were$124.4 million, a decrease from $213.3 million in 2023[6] - Total liabilities as of December 31, 2024, were$36.8 million, down from $54.2 million in 2023[6] Strategic Alternatives - The company is evaluating potential strategic alternatives, including acquisitions and mergers, to maximize stockholder value[1] Securities - The company reported a net unrealized loss on available-for-sale securities of$15, compared to a gain of $274 in Q4 2023[4]